CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 631 enrolled
Drug / intervention
DFN-15 Active +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03009019
NCT03009019Phase 3Completed
CompareCT.gov

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy, Tolerability, and Safety Study of DFN-15 in Episodic Migraine With or Without Aura

BioDelivery Sciences International·interventional·Posted Jan 4, 2017·Updated Jan 10, 2023

In Brief

A Phase 3 clinical trial evaluating DFN-15 Active and DFN-15 Placebo for Migraine Headache. Completed, enrolled 631 participants across 43 sites.

Detailed Summary

Efficacy, Tolerability, and Safety of DFN-15 in episodic migraine with or without aura, being conducted at multiple centers in the United States

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine Headache
CountriesUnited States
CollaboratorsDr. Reddy's Laboratories Limited

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 4, 2017
Enrollment StartDec 1, 2016
Primary CompletionNov 1, 2017
Study CompletionMay 1, 2019
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 9.5 years ago

Interventions

DFN-15 Activedrug

DFN-15 Placeboother